{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T13:38:49Z","timestamp":1779370729408,"version":"3.53.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>APRI and FIB-4 scores are used to exclude clinically significant fibrosis (defined as stage\u2009\u2265\u2009F2) in patients with chronic viral hepatitis. However, the cut-offs for these scores (generated by Youden\u00a0indices) vary between different patient cohorts. This study aimed to evaluate whether serum <jats:underline>d<\/jats:underline>ithiothreitol-<jats:underline>o<\/jats:underline>xidizing <jats:underline>c<\/jats:underline>apacity (DOC), i.e., a surrogate test of quiescin sulfhydryl oxidase-1, which is a matrix remodeling enzyme, could be used to non-invasively identify significant fibrosis in patients with various chronic liver diseases (CLDs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Diagnostic performance of DOC was compared with APRI and FIB-4 for identifying significant fibrosis. ROC curve analyses were undertaken in: a) two chronic hepatitis B (CHB) cohorts, independently established from hospitals in Wenzhou (<jats:italic>n<\/jats:italic>\u2009=\u2009208) and Hefei (<jats:italic>n<\/jats:italic>\u2009=\u2009120); b) a MASLD cohort from Wenzhou hospital (<jats:italic>n<\/jats:italic>\u2009=\u2009122); and c) a cohort with multiple CLD etiologies (except CHB and MASLD; <jats:italic>n<\/jats:italic>\u2009=\u2009102), which was identified from patients in both hospitals. Cut-offs were calculated using the Youden index. All CLD patients (<jats:italic>n<\/jats:italic>\u2009=\u2009552) were then stratified by age for ROC curve analyses and cut-off calculations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Stratified by CLD etiology or age, ROC curve analyses consistently showed that the DOC test was superior to APRI and FIB-4 for discriminating between clinically significant fibrosis and no fibrosis, when APRI and FIB-4 showed poor\/modest diagnostic performance (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01 and <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001 in 3, 1 and 3 cohort comparisons, respectively). Conversely, the DOC test was equivalent to APRI and FIB-4 when all tests showed moderate\/adequate diagnostic performances (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05 in 11 cohort comparisons). DOC had a significant advantage over APRI or FIB-4 scores for establishing a uniform cut-off independently of age and CLD etiology (coefficients of variation of DOC, APRI and FIB-4 cut-offs were 1.7%, 22.9% and 47.6% in cohorts stratified by CLD etiology, 2.0%, 26.7% and 29.5% in cohorts stratified by age, respectively). The uniform cut-off was 2.13, yielded from all patients examined. Surprisingly, the uniform cut-off was the same as the DOC upper limit of normal with a specificity of 99%, estimated from 275 healthy control individuals. Hence, the uniform cut-off should possess a high negative predictive value for excluding significant fibrosis in primary care settings. A high DOC cut-off with 97.5% specificity could be used for detecting significant fibrosis (\u2265\u2009F2) with an acceptable positive predictive value (87.1%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This proof-of-concept study suggests that the DOC test may efficiently rule out and rule in significant liver fibrosis, thereby reducing the numbers of unnecessary liver biopsies. Moreover, the DOC test may be helpful for clinicians to exclude significant liver fibrosis in the general population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-024-03502-z","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T16:02:16Z","timestamp":1719936136000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Serum dithiothreitol-oxidizing capacity (DOC) is a promising biomarker for excluding significant liver fibrosis: a proof-of-concept study"],"prefix":"10.1186","volume":"22","author":[{"given":"Lumin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Zhi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Zhe","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9366-9819","authenticated-orcid":false,"given":"Jinsong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"1","key":"3502_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41575-023-00846-4","volume":"21","author":"G Feng","year":"2024","unstructured":"Feng G, Valenti L, Wong VW, et al. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2024;21(1):46\u201356.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"3502_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/hep.32163","volume":"75","author":"P Gin\u00e8s","year":"2022","unstructured":"Gin\u00e8s P, Castera L, Lammert F, et al. Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology. 2022;75(1):219\u201328.","journal-title":"Hepatology"},{"issue":"21","key":"3502_CR3","doi-asserted-by":"publisher","first-page":"13320","DOI":"10.3390\/ijms232113320","volume":"23","author":"A Lonardo","year":"2022","unstructured":"Lonardo A, Mantovani A, Targher G, Baffy G. Nonalcoholic fatty liver disease and chronic kidney disease: epidemiology, pathogenesis, and clinical and research implications. Int J Mol Sci. 2022;23(21):13320.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3502_CR4","doi-asserted-by":"publisher","first-page":"101479","DOI":"10.1016\/j.aohep.2024.101479","volume":"29","author":"A Lonardo","year":"2024","unstructured":"Lonardo A. Liver fibrosis: more than meets the eye. Ann Hepatol. 2024;29(4):101479.","journal-title":"Ann Hepatol"},{"issue":"9","key":"3502_CR5","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1136\/gutjnl-2012-302826","volume":"62","author":"M Rosselli","year":"2013","unstructured":"Rosselli M, MacNaughtan J, Jalan R, Pinzani M. Beyond scoring: a modern interpretation of disease progression in chronic liver disease. Gut. 2013;62(9):1234\u201341.","journal-title":"Gut"},{"issue":"6","key":"3502_CR6","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","volume":"38","author":"P Bedossa","year":"2003","unstructured":"Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38(6):1449\u201357.","journal-title":"Hepatology"},{"issue":"3","key":"3502_CR7","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.22742","volume":"49","author":"DC Rockey","year":"2009","unstructured":"Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, American Association for the Study of Liver Diseases. Liver biopsy. Hepatology. 2009;49(3):1017\u201344.","journal-title":"Hepatology"},{"issue":"3","key":"3502_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/1751-2980.12854","volume":"21","author":"Chinese Society of Hepatology (Chinese Medical Association)","year":"2020","unstructured":"Chinese Society of Hepatology (Chinese Medical Association), Chinese Society of Gastroenterolog (Chinese Medical Association), Chinese Society of Infectious Diseases (Chinese Medical Association). Consensus on the diagnosis and treatment of hepatic fibrosis (2019). J Dig Dis. 2020;21(3):127\u201338.","journal-title":"J Dig Dis"},{"issue":"1","key":"3502_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","volume":"63","author":"European Association for Study of Liver","year":"2015","unstructured":"European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237\u201364.","journal-title":"J Hepatol"},{"issue":"1","key":"3502_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1\u201398.","journal-title":"Hepatol Int"},{"key":"3502_CR11","unstructured":"World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. 2014. https:\/\/apps.who.int\/iris\/handle\/10665\/111747."},{"key":"3502_CR12","unstructured":"World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. 2015. https:\/\/apps.who.int\/iris\/handle\/10665\/154590."},{"issue":"3","key":"3502_CR13","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/hep.21835","volume":"46","author":"AA Shaheen","year":"2007","unstructured":"Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. 2007;46(3):912\u201321.","journal-title":"Hepatology"},{"issue":"28","key":"3502_CR14","doi-asserted-by":"publisher","first-page":"45768","DOI":"10.18632\/oncotarget.17470","volume":"8","author":"Q Li","year":"2017","unstructured":"Li Q, Lu C, Li W, Huang Y, Chen L. Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B. Oncotarget. 2017;8(28):45768\u201376.","journal-title":"Oncotarget"},{"issue":"5","key":"3502_CR15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajg.2016.453","volume":"112","author":"S McPherson","year":"2017","unstructured":"McPherson S, Hardy T, Dufour JF, et al. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. Am J Gastroenterol. 2017;112(5):740\u201351.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"3502_CR16","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/jmv.25435","volume":"91","author":"W Wang","year":"2019","unstructured":"Wang W, Zhao X, Li G, et al. Diagnostic thresholds and performance of noninvasive fibrosis scores are limited by age in patients with chronic hepatitis B. J Med Virol. 2019;91(7):1279\u201387.","journal-title":"J Med Virol"},{"issue":"6141","key":"3502_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.1238279","volume":"341","author":"T Ilani","year":"2013","unstructured":"Ilani T, Alon A, Grossman I, et al. A secreted disulfide catalyst controls extracellular matrix composition and function. Science. 2013;341(6141):74\u20136.","journal-title":"Science"},{"issue":"2","key":"3502_CR18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1006\/bbrc.2000.2324","volume":"269","author":"D Coppock","year":"2000","unstructured":"Coppock D, Kopman C, Gudas J, Cina-Poppe DA. Regulation of the quiescence-induced genes: quiescin Q6, decorin, and ribosomal protein S29. Biochem Biophys Res Commun. 2000;269(2):604\u201310.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"3502_CR19","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41591-022-01850-y","volume":"28","author":"L Niu","year":"2022","unstructured":"Niu L, Thiele M, Geyer PE, et al. Noninvasive proteomic biomarkers for alcohol-related liver disease. Nat Med. 2022;28(6):1277\u201387.","journal-title":"Nat Med"},{"key":"3502_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.freeradbiomed.2016.08.028","volume":"99","author":"L Zhang","year":"2016","unstructured":"Zhang L, Cheng Q, Zhang L, et al. Serum thioredoxin reductase is highly increased in mice with hepatocellular carcinoma and its activity is restrained by several mechanisms. Free Radic Biol Med. 2016;99:426\u201335.","journal-title":"Free Radic Biol Med"},{"key":"3502_CR21","doi-asserted-by":"publisher","first-page":"101180","DOI":"10.1016\/j.eclinm.2021.101180","volume":"42","author":"L Yang","year":"2021","unstructured":"Yang L, Zhang Y, Zhang K, et al. Evaluation of dithiothreitol-oxidizing capacity (DOC) as a serum biomarker for chronic hepatitis B in patients exhibiting normal alanine aminotransferase levels: a pilot study towards better monitoring of disease. EClinicalMedicine. 2021;42:101180.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"3502_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s12072-022-10420-w","volume":"17","author":"L-J Tang","year":"2023","unstructured":"Tang L-J, Li G, Eslam M, et al. N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD. Hepatol Int. 2023;17(1):190\u2013201.","journal-title":"Hepatol Int"},{"issue":"4","key":"3502_CR23","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/apt.16487","volume":"54","author":"YJ Zhou","year":"2021","unstructured":"Zhou YJ, Gao F, Liu WY, et al. Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2021;54(4):470\u201380.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"3502_CR24","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"issue":"1","key":"3502_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u20139.","journal-title":"J Hepatol"},{"issue":"2","key":"3502_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289\u201393.","journal-title":"Hepatology"},{"issue":"10406","key":"3502_CR27","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0140-6736(23)01174-1","volume":"402","author":"M Serra-Burriel","year":"2023","unstructured":"Serra-Burriel M, Juanola A, Serra-Burriel F, et al. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. Lancet. 2023;402(10406):988\u201396.","journal-title":"Lancet"},{"issue":"3","key":"3502_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.20517\/mtod.2023.23","volume":"3","author":"J Wang","year":"2023","unstructured":"Wang J, Lonardo A. Commentary: Of women, liver, and heart. Metab Target Organ Damage. 2023;3(3):14.","journal-title":"Metab Target Organ Damage"},{"issue":"7","key":"3502_CR29","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.cgh.2017.12.048","volume":"16","author":"L Caballer\u00eda","year":"2018","unstructured":"Caballer\u00eda L, Pera G, Arteaga I, et al. High prevalence of liver fibrosis among european adults with unknown liver disease: a population-based study. Clin Gastroenterol Hepatol. 2018;16(7):1138-45.e5.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"3502_CR30","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"European Association for the Study of the Liver","year":"2021","unstructured":"European Association for the Study of the Liver, Clinical Practice Guideline Panel, EASL Governing Board representative. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659\u201389.","journal-title":"J Hepatol"},{"key":"3502_CR31","unstructured":"LiverRisk score online calculator. https:\/\/www.liverriskscore.com."},{"issue":"4","key":"3502_CR32","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol. 2018;69(4):896\u2013904.","journal-title":"J Hepatol"},{"key":"3502_CR33","doi-asserted-by":"crossref","unstructured":"Miao L, Targher G, Byrne CD, Cao YY, Zheng MH. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024;S1043-2760(24):36-5.","DOI":"10.1016\/j.tem.2024.02.007"},{"issue":"4","key":"3502_CR34","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","volume":"17","author":"XD Zhou","year":"2023","unstructured":"Zhou XD, Targher G, Byrne CD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023;17(4):773\u201391.","journal-title":"Hepatol Int"},{"issue":"4","key":"3502_CR35","doi-asserted-by":"publisher","first-page":"386","DOI":"10.18632\/oncotarget.27438","volume":"11","author":"T Feldman","year":"2020","unstructured":"Feldman T, Grossman-Haham I, Elkis Y, et al. Inhibition of fibroblast secreted QSOX1 perturbs extracellular matrix in the tumor microenvironment and decreases tumor growth and metastasis in murine cancer models. Oncotarget. 2020;11(4):386\u201398.","journal-title":"Oncotarget"},{"issue":"1","key":"3502_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/pro.3537","volume":"28","author":"G Javitt","year":"2019","unstructured":"Javitt G, Grossman-Haham I, Alon A, et al. cis-Proline mutants of quiescin sulfhydryl oxidase 1 with altered redox properties undermine extracellular matrix integrity and cell adhesion in fibroblast cultures. Protein Sci. 2019;28(1):228\u201338.","journal-title":"Protein Sci"},{"issue":"7","key":"3502_CR37","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1002\/jex2.48","volume":"1","author":"CS Millar-Haskell","year":"2022","unstructured":"Millar-Haskell CS, Sperduto JL, Slater JH, Thorpe C, Gleghorn JP. Secretion of the disulfide bond generating catalyst QSOX1 from pancreatic tumor cells into the extracellular matrix: association with extracellular vesicles and matrix proteins. J Extracell Biol. 2022;1(7):e48.","journal-title":"J Extracell Biol"},{"issue":"4","key":"3502_CR38","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1074\/mcp.M113.034595","volume":"13","author":"ES Baker","year":"2014","unstructured":"Baker ES, Burnum-Johnson KE, Jacobs JM, et al. Advancing the high throughput identification of liver fibrosis protein signatures using multiplexed ion mobility spectrometry. Mol Cell Proteomics. 2014;13(4):1119\u201327.","journal-title":"Mol Cell Proteomics"},{"issue":"2","key":"3502_CR39","doi-asserted-by":"publisher","first-page":"100067","DOI":"10.1016\/j.jhepr.2020.100067","volume":"2","author":"K Patel","year":"2020","unstructured":"Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2(2):100067.","journal-title":"JHEP Rep"},{"key":"3502_CR40","doi-asserted-by":"publisher","first-page":"101942","DOI":"10.1016\/j.redox.2021.101942","volume":"41","author":"J Sun","year":"2021","unstructured":"Sun J, Zhou C, Zhao Y, et al. Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation. Redox Biol. 2021;41:101942.","journal-title":"Redox Biol"},{"issue":"18","key":"3502_CR41","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1093\/eurheartj\/ehs162","volume":"33","author":"A Mebazaa","year":"2012","unstructured":"Mebazaa A, Vanpoucke G, Thomas G, et al. Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. Eur Heart J. 2012;33(18):2317\u201324.","journal-title":"Eur Heart J"},{"issue":"4","key":"3502_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.20517\/mtod.2022.20","volume":"2","author":"A Lonardo","year":"2022","unstructured":"Lonardo A, Ndrepepa G. Concise review: gamma-glutamyl transferase - evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk. Metab Target Organ Damage. 2022;2(4):17.","journal-title":"Metab Target Organ Damage"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03502-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03502-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03502-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T16:03:34Z","timestamp":1719936214000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03502-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3502"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03502-z","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"18 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the study was obtained from the First Affiliated Hospital of Wenzhou Medical University (Approval No. 2016\u2013246) and the Second Hospital of Anhui Medical University (Approval No. 20180347), and all participants provided informed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JZ has a Chinese Patent associated with measurement of total thiol-oxidizing capacity in serum. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"278"}}